Author

Trever G. Bivona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Abby Marquez· 1 shared Adrian L. Gill· 1 shared Aleah F. Caulin· 1 shared Anibal R. Cordero· 1 shared Ashley Maynard· 1 shared Beatrice GiniiD· 1 shared Carlos Stahlhut· 1 shared Caroline E. McCoach· 1 shared

Activity by Year

2017-2017 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abby Marquez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 14, 2017

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

Robert J. Nichols, Franziska Haderk, Carlos Stahlhut…·Trever G. Bivona

This study shows that inhibiting SHP2 phosphatase effectively targets cancers driven by nucleotide-cycling RAS, RAS-GTP dependent BRAF, or NF1 loss by disrupting RAS-RAF-MEK-ERK signaling.

DOI 10.1101/188730

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 16, 2017

Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers

Collin M. Blakely, Thomas B.K. Watkins, Wei Wu…·Trever G. Bivona

The paper investigates genetic epistasis in EGFR-mutant lung cancers using over 2,000 cases, showing that genetic combinations, not single drivers, dominate tumor progression and clinical outcomes.

DOI 10.1101/117291

humanwhole-exome sequencing

𝕏 PostBluesky